ODI Pharma AB (“ODI Pharma”) has been informed that Mr. Niclas Kappelin has acquired 20’000 shares in ODI Pharma and exceeded the threshold of five (5) percent on 9 July 2021.
Mr. Niclas Kappelin has informed the company that he has acquired 20’000 shares in ODI Pharma and reached above the level of 5 percent of the total number of shares and voting rights in the company. Niclas Kappelin’s holdings after the transaction amounts to a total of 780’900 shares, corresponding to approximately 5.13 percent of the shares and voting rights in ODI Pharma.
Previously, Niclas Kappelin held 760’900 shares in the company, corresponding to approximately 4,99 percent of the shares and voting rights in ODI Pharma.
"I'm pleased to be a part of ODI Pharma's exciting future. It's not every day an opportunity is given to invest in a newly started company having a strong business model in a very new business area. The fact that ODI Pharma doesn't have any large cash burn until sales has been generated is a very solid management approach which clearly demonstrates commitment. ODI Pharma's medical grade cannabis and their skin care products branded kandol. are two areas where I expect significant growth potential and to enter as a larger shareholder now at the beginning of the development is the right thing to do.” – says Niclas Kappelin.
For more information on ODI Pharma, please contact:
Derek Simmross, CEO, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.
